within Pharmacolibrary.Drugs.ATC.A;

model A03BB03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 0.000125,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A03BB03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Methylscopolamine is a quaternary ammonium derivative of scopolamine and acts as a muscarinic acetylcholine receptor antagonist. It is primarily used as an antispasmodic agent to relieve smooth muscle spasms in the gastrointestinal tract as well as to reduce salivation and other secretions. Due to its poor ability to cross the blood-brain barrier, it has fewer central nervous system effects than scopolamine. It is still available in some countries for gastrointestinal and other spasm-related disorders.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adult oral administration. No published clinical pharmacokinetic studies with specific quantitative PK parameters for methylscopolamine found.</p><h4>References</h4><ol><li><p>Salehi, S, et al., &amp; Birkhed, D (2013). Oral rehydration therapy products - a plaque pH study under normal and dry mouth conditions. <i>International dental journal</i> 63(5) 254–258. DOI:<a href=\"https://doi.org/10.1111/idj.12041\">10.1111/idj.12041</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24074020/\">https://pubmed.ncbi.nlm.nih.gov/24074020</a></p></li><li><p>Oki, T, et al., &amp; Yamada, S (2007). Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder. <i>The Journal of urology</i> 177(2) 766–770. DOI:<a href=\"https://doi.org/10.1016/j.juro.2006.09.079\">10.1016/j.juro.2006.09.079</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17222678/\">https://pubmed.ncbi.nlm.nih.gov/17222678</a></p></li><li><p>Oki, T, et al., &amp; Yamada, S (2006). Advantages for transdermal over oral oxybutynin to treat overactive bladder: Muscarinic receptor binding, plasma drug concentration, and salivary secretion. <i>The Journal of pharmacology and experimental therapeutics</i> 316(3) 1137–1145. DOI:<a href=\"https://doi.org/10.1124/jpet.105.094508\">10.1124/jpet.105.094508</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16282521/\">https://pubmed.ncbi.nlm.nih.gov/16282521</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A03BB03;
